Transforming Hypertrophic Cardiomyopathy Care
The Senior Manager, Regulatory Affairs will play a key role in Braveheart Bio’s global regulatory submissions, spanning U.S. IND and NDA activities and ex-U.S. CTA and MAA activities. Reporting to the Vice President of Regulatory Affairs, this individual will prepare and manage submissions to global health authorities and help develop and execute regulatory strategy. The role requires strong knowledge of U.S. FDA regulations, the EU Clinical Trials Regulation, and hands-on experience navigating country-specific requirements in regions outside the U.S.
Advancing treatments to improve outcomes and quality of life for patients with hypertrophic cardiomyopathy and related heart conditions.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Transforming Hypertrophic Cardiomyopathy Care.